Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Cell Biol ; 24(4): 554-564, 2022 04.
Article in English | MEDLINE | ID: mdl-35411083

ABSTRACT

Epithelial-mesenchymal transition (EMT) programs operate within carcinoma cells, where they generate phenotypes associated with malignant progression. In their various manifestations, EMT programs enable epithelial cells to enter into a series of intermediate states arrayed along the E-M phenotypic spectrum. At present, we lack a coherent understanding of how carcinoma cells control their entrance into and continued residence in these various states, and which of these states favour the process of metastasis. Here we characterize a layer of EMT-regulating machinery that governs E-M plasticity (EMP). This machinery consists of two chromatin-modifying complexes, PRC2 and KMT2D-COMPASS, which operate as critical regulators to maintain a stable epithelial state. Interestingly, loss of these two complexes unlocks two distinct EMT trajectories. Dysfunction of PRC2, but not KMT2D-COMPASS, yields a quasi-mesenchymal state that is associated with highly metastatic capabilities and poor survival of patients with breast cancer, suggesting that great caution should be applied when PRC2 inhibitors are evaluated clinically in certain patient cohorts. These observations identify epigenetic factors that regulate EMP, determine specific intermediate EMT states and, as a direct consequence, govern the metastatic ability of carcinoma cells.


Subject(s)
Breast Neoplasms , Carcinoma , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Clustered Regularly Interspaced Short Palindromic Repeats , Epithelial Cells/pathology , Epithelial-Mesenchymal Transition/genetics , Female , Humans , Neoplasm Metastasis/pathology
2.
Nature ; 586(7827): 120-126, 2020 10.
Article in English | MEDLINE | ID: mdl-32968282

ABSTRACT

The genetic circuits that allow cancer cells to evade destruction by the host immune system remain poorly understood1-3. Here, to identify a phenotypically robust core set of genes and pathways that enable cancer cells to evade killing mediated by cytotoxic T lymphocytes (CTLs), we performed genome-wide CRISPR screens across a panel of genetically diverse mouse cancer cell lines that were cultured in the presence of CTLs. We identify a core set of 182 genes across these mouse cancer models, the individual perturbation of which increases either the sensitivity or the resistance of cancer cells to CTL-mediated toxicity. Systematic exploration of our dataset using genetic co-similarity reveals the hierarchical and coordinated manner in which genes and pathways act in cancer cells to orchestrate their evasion of CTLs, and shows that discrete functional modules that control the interferon response and tumour necrosis factor (TNF)-induced cytotoxicity are dominant sub-phenotypes. Our data establish a central role for genes that were previously identified as negative regulators of the type-II interferon response (for example, Ptpn2, Socs1 and Adar1) in mediating CTL evasion, and show that the lipid-droplet-related gene Fitm2 is required for maintaining cell fitness after exposure to interferon-γ (IFNγ). In addition, we identify the autophagy pathway as a conserved mediator of the evasion of CTLs by cancer cells, and show that this pathway is required to resist cytotoxicity induced by the cytokines IFNγ and TNF. Through the mapping of cytokine- and CTL-based genetic interactions, together with in vivo CRISPR screens, we show how the pleiotropic effects of autophagy control cancer-cell-intrinsic evasion of killing by CTLs and we highlight the importance of these effects within the tumour microenvironment. Collectively, these data expand our knowledge of the genetic circuits that are involved in the evasion of the immune system by cancer cells, and highlight genetic interactions that contribute to phenotypes associated with escape from killing by CTLs.


Subject(s)
Genome/genetics , Genomics , Neoplasms/genetics , Neoplasms/immunology , T-Lymphocytes, Cytotoxic/immunology , Tumor Escape/genetics , Tumor Escape/immunology , Animals , Autophagy , Cell Line, Tumor , Female , Genes, Neoplasm/genetics , Humans , Interferon-gamma/immunology , Male , Mice , NF-kappa B/metabolism , Reproducibility of Results , Signal Transduction
3.
Sci Transl Med ; 10(436)2018 04 11.
Article in English | MEDLINE | ID: mdl-29643230

ABSTRACT

Patients undergoing surgical resection of primary breast tumors confront a risk for metastatic recurrence that peaks sharply 12 to 18 months after surgery. The cause of early metastatic relapse in breast cancer has long been debated, with many ascribing these relapses to the natural progression of the disease. Others have proposed that some aspect of surgical tumor resection triggers the outgrowth of otherwise-dormant metastases, leading to the synchronous pattern of relapse. Clinical data cannot distinguish between these hypotheses, and previous experimental approaches have not provided clear answers. Such uncertainty hinders the development and application of therapeutic approaches that could potentially reduce early metastatic relapse. We describe an experimental model system that definitively links surgery and the subsequent wound-healing response to the outgrowth of tumor cells at distant anatomical sites. Specifically, we find that the systemic inflammatory response induced after surgery promotes the emergence of tumors whose growth was otherwise restricted by a tumor-specific T cell response. Furthermore, we demonstrate that perioperative anti-inflammatory treatment markedly reduces tumor outgrowth in this model, suggesting that similar approaches might substantially reduce early metastatic recurrence in breast cancer patients.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Animals , Biomarkers, Tumor/immunology , Breast Neoplasms/immunology , CD8-Positive T-Lymphocytes/metabolism , Cell Line, Tumor , Female , Mice , Neoplasm Metastasis/immunology , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/metabolism
4.
Cancer Discov ; 6(6): 630-49, 2016 06.
Article in English | MEDLINE | ID: mdl-27072748

ABSTRACT

UNLABELLED: Immune cells promote the initial metastatic dissemination of carcinoma cells from primary tumors. In contrast to their well-studied functions in the initial stages of metastasis, the specific roles of immunocytes in facilitating progression through the critical later steps of the invasion-metastasis cascade remain poorly understood. Here, we define novel functions of neutrophils in promoting intraluminal survival and extravasation at sites of metastatic dissemination. We show that CD11b(+)/Ly6G(+) neutrophils enhance metastasis formation via two distinct mechanisms. First, neutrophils inhibit natural killer cell function, which leads to a significant increase in the intraluminal survival time of tumor cells. Thereafter, neutrophils operate to facilitate extravasation of tumor cells through the secretion of IL1ß and matrix metalloproteinases. These results identify neutrophils as key regulators of intraluminal survival and extravasation through their cross-talk with host cells and disseminating carcinoma cells. SIGNIFICANCE: This study provides important insights into the systemic contributions of neutrophils to cancer metastasis by identifying how neutrophils facilitate intermediate steps of the invasion-metastasis cascade. We demonstrate that neutrophils suppress natural killer cell activity and increase extravasation of tumor cells. Cancer Discov; 6(6); 630-49. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 561.


Subject(s)
Carcinoma/immunology , Carcinoma/pathology , Killer Cells, Natural/immunology , Neutrophils/immunology , Adoptive Transfer , Animals , Biomarkers , Carcinoma/genetics , Carcinoma/metabolism , Cell Communication , Cell Line, Tumor , Cell Movement , Cell Survival , Cytokines/biosynthesis , Disease Models, Animal , Endothelial Cells/metabolism , Heterografts , Humans , Immunity, Innate , Immunophenotyping , Killer Cells, Natural/metabolism , Matrix Metalloproteinases/metabolism , Mice , Mice, Knockout , Neoplasm Invasiveness , Neoplasm Metastasis , Neutrophils/metabolism , Phenotype
5.
Science ; 351(6277): aad3680, 2016 Mar 04.
Article in English | MEDLINE | ID: mdl-26941323

ABSTRACT

The epithelial-to-mesenchymal transition enables carcinoma cells to acquire malignancy-associated traits and the properties of tumor-initiating cells (TICs). TICs have emerged in recent years as important targets for cancer therapy, owing to their ability to drive clinical relapse and enable metastasis. Here, we propose a strategy to eliminate mesenchymal TICs by inducing their conversion to more epithelial counterparts that have lost tumor-initiating ability. We report that increases in intracellular levels of the second messenger, adenosine 3',5'-monophosphate, and the subsequent activation of protein kinase A (PKA) induce a mesenchymal-to-epithelial transition (MET) in mesenchymal human mammary epithelial cells. PKA activation triggers epigenetic reprogramming of TICs by the histone demethylase PHF2, which promotes their differentiation and loss of tumor-initiating ability. This study provides proof-of-principle for inducing an MET as differentiation therapy for TICs and uncovers a role for PKA in enforcing and maintaining the epithelial state.


Subject(s)
Adenosine Monophosphate/metabolism , Breast Neoplasms/pathology , Cell Transformation, Neoplastic/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Epithelial-Mesenchymal Transition , Neoplastic Stem Cells/metabolism , Second Messenger Systems , Animals , Breast Neoplasms/metabolism , Cell Line, Tumor , Cell Transformation, Neoplastic/pathology , Cholera Toxin/pharmacology , Colforsin/pharmacology , Cyclic AMP-Dependent Protein Kinases/genetics , Enzyme Activation , Epigenesis, Genetic , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , Histone Demethylases/metabolism , Homeodomain Proteins/metabolism , Humans , Mammary Glands, Human/metabolism , Mammary Glands, Human/pathology , Mesoderm/drug effects , Mesoderm/metabolism , Mesoderm/pathology , Mice , Neoplastic Stem Cells/pathology , Xenograft Model Antitumor Assays
6.
Cancer Cell ; 24(3): 347-64, 2013 Sep 09.
Article in English | MEDLINE | ID: mdl-24029232

ABSTRACT

The epithelial-mesenchymal transition program becomes activated during malignant progression and can enrich for cancer stem cells (CSCs). We report that inhibition of protein kinase C α (PKCα) specifically targets CSCs but has little effect on non-CSCs. The formation of CSCs from non-stem cells involves a shift from EGFR to PDGFR signaling and results in the PKCα-dependent activation of FRA1. We identified an AP-1 molecular switch in which c-FOS and FRA1 are preferentially utilized in non-CSCs and CSCs, respectively. PKCα and FRA1 expression is associated with the aggressive triple-negative breast cancers, and the depletion of FRA1 results in a mesenchymal-epithelial transition. Hence, identifying molecular features that shift between cell states can be exploited to target signaling components critical to CSCs.


Subject(s)
Breast Neoplasms/metabolism , Neoplastic Stem Cells/metabolism , Protein Kinase C-alpha/metabolism , Signal Transduction , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Cluster Analysis , Epithelial-Mesenchymal Transition/genetics , ErbB Receptors/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Protein Kinase C-alpha/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-fos/genetics , Proto-Oncogene Proteins c-fos/metabolism , Receptors, Platelet-Derived Growth Factor/metabolism , Signal Transduction/drug effects , Snail Family Transcription Factors , Transcription Factors/metabolism , Twist-Related Protein 1/metabolism
7.
PLoS One ; 6(1): e15945, 2011 Jan 10.
Article in English | MEDLINE | ID: mdl-21264347

ABSTRACT

Signaling mediated by the Epidermal Growth Factor Receptor (EGFR) is crucial in normal development, and aberrant EGFR signaling has been implicated in a wide variety of cancers. Here we find that the high- and low-affinity interactions between EGFR and its ligands activate different signaling pathways. While high-affinity ligand binding is sufficient for activation of most canonical signaling pathways, low-affinity binding is required for the activation of the Signal transducers and activators of transcription (Stats) and Phospholipase C-gamma 1 (PLCγ1). As the Stat proteins are involved in many cellular responses including proliferation, migration and apoptosis, these results assign a function to low-affinity interactions that has been omitted from computational models of EGFR signaling. The existence of receptors with distinct signaling properties provides a way for EGFR to respond to different concentrations of the same ligand in qualitatively different ways.


Subject(s)
ErbB Receptors/metabolism , Signal Transduction , Cell Line , Humans , Ligands , Phospholipase C gamma/metabolism , Protein Binding , STAT Transcription Factors/metabolism
8.
Mol Syst Biol ; 5: 235, 2009.
Article in English | MEDLINE | ID: mdl-19156127

ABSTRACT

Receptor tyrosine kinases (RTKs) process extracellular cues by activating a broad array of signaling proteins. Paradoxically, they often use the same proteins to elicit diverse and even opposing phenotypic responses. Binary, 'on-off' wiring diagrams are therefore inadequate to explain their differences. Here, we show that when six diverse RTKs are placed in the same cellular background, they activate many of the same proteins, but to different quantitative degrees. Additionally, we find that the relative phosphorylation levels of upstream signaling proteins can be accurately predicted using linear models that rely on combinations of receptor-docking affinities and that the docking sites for phosphoinositide 3-kinase (PI3K) and Shc1 provide much of the predictive information. In contrast, we find that the phosphorylation levels of downstream proteins cannot be predicted using linear models. Taken together, these results show that information processing by RTKs can be segmented into discrete upstream and downstream steps, suggesting that the challenging task of constructing mathematical models of RTK signaling can be parsed into separate and more manageable layers.


Subject(s)
Receptor Protein-Tyrosine Kinases/metabolism , Signal Transduction , Binding Sites , Phosphatidylinositol 3-Kinases/metabolism , Phosphorylation , Shc Signaling Adaptor Proteins/metabolism , Src Homology 2 Domain-Containing, Transforming Protein 1
9.
Nature ; 439(7073): 168-74, 2006 Jan 12.
Article in English | MEDLINE | ID: mdl-16273093

ABSTRACT

Although epidermal growth factor receptor (EGFR; also called ErbB1) and its relatives initiate one of the most well-studied signalling networks, there is not yet a genome-wide view of even the earliest step in this pathway: recruitment of proteins to the activated receptors. Here we use protein microarrays comprising virtually every Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain encoded in the human genome to measure the equilibrium dissociation constant of each domain for 61 peptides representing physiological sites of tyrosine phosphorylation on the four ErbB receptors. This involved 77,592 independent biochemical measurements and provided a quantitative protein interaction network that reveals many new interactions, including ones that fall outside of our current view of domain selectivity. By slicing through the network at different affinity thresholds, we found surprising differences between the receptors. Most notably, EGFR and ErbB2 become markedly more promiscuous as the threshold is lowered, whereas ErbB3 does not. Because EGFR and ErbB2 are overexpressed in many human cancers, our results suggest that the extent to which promiscuity changes with protein concentration may contribute to the oncogenic potential of receptor tyrosine kinases, and perhaps other signalling proteins as well.


Subject(s)
ErbB Receptors/chemistry , ErbB Receptors/metabolism , Protein Array Analysis , Cell Line , Computational Biology , Genomics , Humans , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Phosphopeptides/chemistry , Phosphopeptides/metabolism , Phosphorylation , Phosphotyrosine/metabolism , Protein Binding , Protein Structure, Tertiary , Software , Surface Plasmon Resonance , src Homology Domains
SELECTION OF CITATIONS
SEARCH DETAIL
...